The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

"This high global demand is largely driven by the ongoing challenges posed by bone defects, particularly following trauma or surgical interventions such as tumor excision," said Dr. Whyte ...

The smaller incision allows for many benefits, including minimal to no blood loss, less to no opioids prescribed post-op, less tissue disruption and bone resection, less post-op pain, faster ...

The operation to remove the temporal bone is called a mastoidectomy or temporal bone resection. Rarely, your surgeon might need to remove the facial nerve. This runs down the side of the face and ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

Compared with placebo, a preoperative and intraoperative infusion of tranexamic acid was associated with significant ...

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...